Iron isomaltoside 1000 is under investigation in Iron Deficiency Anaemia. Iron isomaltoside 1000 has been investigated for the treatment and basic science of Anemia, Gastric Cancer, Esophageal Cancer, Chronic Kidney Disease, and Anemia, Iron-Deficiency, among others.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Dimercaprol | Dimercaprol may increase the nephrotoxic activities of Iron isomaltoside 1000. |
| Deferiprone | The serum concentration of Deferiprone can be decreased when it is combined with Iron isomaltoside 1000. |
| Methyldopa | Iron isomaltoside 1000 can cause a decrease in the absorption of Methyldopa resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Moxifloxacin | Iron isomaltoside 1000 can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Grepafloxacin | Iron isomaltoside 1000 can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Enoxacin | Iron isomaltoside 1000 can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Pefloxacin | Iron isomaltoside 1000 can cause a decrease in the absorption of Pefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ciprofloxacin | Iron isomaltoside 1000 can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Trovafloxacin | Iron isomaltoside 1000 can cause a decrease in the absorption of Trovafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Nalidixic acid | Iron isomaltoside 1000 can cause a decrease in the absorption of Nalidixic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Rosoxacin | Iron isomaltoside 1000 can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cinoxacin | Iron isomaltoside 1000 can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Lomefloxacin | Iron isomaltoside 1000 can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Gatifloxacin | Iron isomaltoside 1000 can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Norfloxacin | Iron isomaltoside 1000 can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Levofloxacin | Iron isomaltoside 1000 can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Gemifloxacin | Iron isomaltoside 1000 can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ofloxacin | Iron isomaltoside 1000 can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sparfloxacin | Iron isomaltoside 1000 can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Temafloxacin | Iron isomaltoside 1000 can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Fleroxacin | Iron isomaltoside 1000 can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Technetium Tc-99m ciprofloxacin | Iron isomaltoside 1000 can cause a decrease in the absorption of Technetium Tc-99m ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Garenoxacin | Iron isomaltoside 1000 can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Nemonoxacin | Iron isomaltoside 1000 can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Flumequine | Iron isomaltoside 1000 can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Enrofloxacin | Iron isomaltoside 1000 can cause a decrease in the absorption of Enrofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Orbifloxacin | Iron isomaltoside 1000 can cause a decrease in the absorption of Orbifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sarafloxacin | Iron isomaltoside 1000 can cause a decrease in the absorption of Sarafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Difloxacin | Iron isomaltoside 1000 can cause a decrease in the absorption of Difloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Pazufloxacin | Iron isomaltoside 1000 can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Prulifloxacin | Iron isomaltoside 1000 can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Delafloxacin | Iron isomaltoside 1000 can cause a decrease in the absorption of Delafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sitafloxacin | Iron isomaltoside 1000 can cause a decrease in the absorption of Sitafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Oxolinic acid | Iron isomaltoside 1000 can cause a decrease in the absorption of Oxolinic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Rufloxacin | Iron isomaltoside 1000 can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Pipemidic acid | Iron isomaltoside 1000 can cause a decrease in the absorption of Pipemidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Triethylenetetramine | Triethylenetetramine can cause a decrease in the absorption of Iron isomaltoside 1000 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Pancrelipase | Pancrelipase can cause a decrease in the absorption of Iron isomaltoside 1000 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Pamidronic acid | Iron isomaltoside 1000 can cause a decrease in the absorption of Pamidronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Zoledronic acid | Iron isomaltoside 1000 can cause a decrease in the absorption of Zoledronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Alendronic acid | Iron isomaltoside 1000 can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ibandronate | Iron isomaltoside 1000 can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Clodronic acid | Iron isomaltoside 1000 can cause a decrease in the absorption of Clodronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Risedronic acid | Iron isomaltoside 1000 can cause a decrease in the absorption of Risedronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Etidronic acid | Iron isomaltoside 1000 can cause a decrease in the absorption of Etidronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Tiludronic acid | Iron isomaltoside 1000 can cause a decrease in the absorption of Tiludronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Incadronic acid | Iron isomaltoside 1000 can cause a decrease in the absorption of Incadronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| 3-Aza-2,3-Dihydrogeranyl Diphosphate | Iron isomaltoside 1000 can cause a decrease in the absorption of 3-Aza-2,3-Dihydrogeranyl Diphosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Thiopyrophosphate | Iron isomaltoside 1000 can cause a decrease in the absorption of Thiopyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Geranyl Diphosphate | Iron isomaltoside 1000 can cause a decrease in the absorption of Geranyl Diphosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Pyrophosphoric acid | Iron isomaltoside 1000 can cause a decrease in the absorption of Pyrophosphoric acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| OXI-4503 | Iron isomaltoside 1000 can cause a decrease in the absorption of OXI-4503 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Geranylgeranyl diphosphate | Iron isomaltoside 1000 can cause a decrease in the absorption of Geranylgeranyl diphosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferric pyrophosphate | Iron isomaltoside 1000 can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Monopotassium phosphate | Iron isomaltoside 1000 can cause a decrease in the absorption of Monopotassium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dipotassium phosphate | Iron isomaltoside 1000 can cause a decrease in the absorption of Dipotassium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sodium phosphate, monobasic | Iron isomaltoside 1000 can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Calcium Phosphate | Iron isomaltoside 1000 can cause a decrease in the absorption of Calcium Phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sodium tripolyphosphate | Iron isomaltoside 1000 can cause a decrease in the absorption of Sodium tripolyphosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferric pyrophosphate citrate | Iron isomaltoside 1000 can cause a decrease in the absorption of Ferric pyrophosphate citrate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Calcium phosphate dihydrate | Iron isomaltoside 1000 can cause a decrease in the absorption of Calcium phosphate dihydrate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Phosphate ion | Iron isomaltoside 1000 can cause a decrease in the absorption of Phosphate ion resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Technetium Tc-99m oxidronate | Iron isomaltoside 1000 can cause a decrease in the absorption of Technetium Tc-99m oxidronate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Omeprazole | The absorption of Iron isomaltoside 1000 can be decreased when combined with Omeprazole. |
| Carbidopa | Iron isomaltoside 1000 can cause a decrease in the absorption of Carbidopa resulting in a reduced serum concentration and potentially a decrease in efficacy. |